NMC
REGN icon

Nine Masts Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Nine Masts Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,393
Closed -$2.42M – 146
2024
Q4 		$2.42M Buy
+3,393
New +$2.85M 0.42% 23
2017
Q3 		– Sell
-1,899
Closed -$933K – 251
2017
Q2 		$933K Buy
+1,899
New +$831K 0.11% 61

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nine Masts Capital's REGN Position: Q1 2025 in Review

Nine Masts Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 3,393 shares — an estimated $2.42M sold.

Nine Masts Capital first reported a position in REGN in Q2 2017 and held it in 2 quarters. The position peaked at $2.42M in Q4 2024. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Nine Masts Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Nine Masts Capital sold 3,393 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $2.42M.
  • Nine Masts Capital first reported a position in Regeneron Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Nine Masts Capital's Regeneron Pharmaceuticals position peaked at $2.42M in Q4 2024.
  • 1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Nine Masts Capital's 13F filing for Q1 2025, filed 13 May 2025.